A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 01 Mar 2017 Status changed from active, no longer recruiting to completed.
- 24 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
- 24 Aug 2016 Status changed from recruiting to active, no longer recruiting.